Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations

Charlotte Pawlyn, Lorenzo Melchor, Alex Murison, Christopher P. Wardell, Annamaria Brioli, Eileen M. Boyle, Martin F. Kaiser, Brian A. Walker, Dil B. Begum, Nasrin B. Dahir, Paula Proszek, Walter M. Gregory, Mark T. Drayson, Graham H. Jackson, Fiona M. Ross, Faith E. Davies, Gareth J. Morgan

Blood (2015) 125 (5): 831–840.

https://doi.org/10.1182/blood-2014-07-584268

Published: 2015

Includes: Supplemental data

Journal Articles

Surface IgM Levels Independently Influence Clinical Behavior and Associate with Altered Phenotype and Genetics in Chronic Lymphocytic Leukemia

Samantha J Drennan, PhD, Annalisa D'Avola, MSc, Ian Tracy, Isla Henderson, Marta Larrayoz, PhD, Carina Mundy, Andrew S. Duncombe, MD, Andrew J. Davies, MD PhD, Davide Rossi, MD PhD, Fiona M Ross, DPhil, Laura Chiecchio, PhD, Kathleen N. Potter, PhD, Jonathan Strefford, PhD, Andrew J Steele, PhD, Peter W Johnson, MD, Graham Packham, PhD, Freda K Stevenson, DPhil, Francesco Forconi, MD DM, PhD FRCPath

Blood (2014) 124 (21): 830.

https://doi.org/10.1182/blood.V124.21.830.830

Published: 2014

Journal Articles

Expression Quantitative Trait Loci Reveal Regulatory Regions Important In The Pathogenesis of Multiple Myeloma

Blood (2013) 122 (21): 1847.

https://doi.org/10.1182/blood.V122.21.1847.1847

Published: 2013

Journal Articles

Co-Existent Hyperdiploidy Does Not Abrogate The Poor Prognosis Associated With Adverse Cytogenetics In Myeloma

Charlotte Pawlyn, MD, Lorenzo Melchor, PhD, Eileen M Boyle, MD, Annamaria Brioli, MD, Martin F Kaiser, MD, Walter Gregory, PhD, Mark T Drayson, MD PhD, Graham Jackson, MD, Fiona M Ross, DPhil, J. Anthony Child, MD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2013) 122 (21): 529.

https://doi.org/10.1182/blood.V122.21.529.529

Published: 2013

Journal Articles

Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells

Brian A. Walker, Christopher P. Wardell, David C. Johnson, Martin F. Kaiser, Dil B. Begum, Nasrin B. Dahir, Fiona M. Ross, Faith E. Davies, David Gonzalez, Gareth J. Morgan

Blood (2013) 121 (17): 3413–3419.

https://doi.org/10.1182/blood-2012-12-471888

Published: 2013

Includes: Supplemental data

Journal Articles

The Impact of Thalidomide Maintenance Therapy Varies Dependent Upon Biological Risk Grouping

Annamaria Brioli, MD, Fiona M Ross, DPhil, Martin F Kaiser, MD, Charlotte Pawlyn, MD, Ping Wu, MBBS, MSc, Walter M Gregory, PhD, Roger G Owen, MD, Graham H Jackson, MD, Michele Cavo, MD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD

Blood (2012) 120 (21): 199.

https://doi.org/10.1182/blood.V120.21.199.199

Published: 2012

Journal Articles

Base-Pair Resolution Mapping of IGH Translocations in Multiple Myeloma Using Targeted Capture and Massively Parallel Sequencing

Brian A Walker, BSc, PhD, Christopher P Wardell, PhD, Dil B Begum, BSc, Nasrin B Dahir, BSc, Fiona M Ross, DPhil, Faith E. Davies, MD, David Gonzalez, PhD, Gareth J. Morgan, MD PhD

Blood (2012) 120 (21): 3490.

https://doi.org/10.1182/blood.V120.21.3490.3490

Published: 2012

Journal Articles

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

Gareth J. Morgan, Walter M. Gregory, Faith E. Davies, Sue E. Bell, Alexander J. Szubert, Julia M. Brown, Nuria N. Coy, Gordon Cook, Nigel H. Russell, Claudius Rudin, Huw Roddie, Mark T. Drayson, Roger G. Owen, Fiona M. Ross, Graham H. Jackson, J. Anthony Child, on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group

Blood (2012) 119 (1): 7–15.

https://doi.org/10.1182/blood-2011-06-357038

Published: 2012

Includes: Supplemental data

Journal Articles

MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease

Gareth J Morgan, MD PhD, Faith E Davies, MD, Walter M Gregory, PhD, Sue E Bell, DPhil, Alex J Szubert, MSc, Gordon Cook, Mark T Drayson, MD, Roger G Owen, MD, Fiona M Ross, DPhil, Graham H Jackson, MD, J. Anthony Child, MD

Blood (2011) 118 (21): 993.

https://doi.org/10.1182/blood.V118.21.993.993

Published: 2011

Journal Articles

The Interaction of Response and FISH-Based Risk Stratification to Better Define Clinical Outcome in Myeloma

Kevin D Boyd, MD, Fiona M Ross, DPhil, Mark T Drayson, MD, Roger G Owen, MD, Alex J Szubert, MSc, Walter M Gregory, PhD, Christopher P Wardell, PhD, Faith E Davies, MD, Graham H Jackson, MD, PhD, J. Anthony Child, MD, Gareth J Morgan, MD PhD

Blood (2011) 118 (21): 1823.

https://doi.org/10.1182/blood.V118.21.1823.1823

Published: 2011

Journal Articles

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Nigel H. Russell, Sue E. Bell, Alexander J. Szubert, Nuria Navarro Coy, Gordon Cook, Sylvia Feyler, Jenny L. Byrne, Huw Roddie, Claudius Rudin, Mark T. Drayson, Roger G. Owen, Fiona M. Ross, Graham H. Jackson, J. Anthony Child, for the NCRI Haematological Oncology Study Group

Blood (2011) 118 (5): 1231–1238.

https://doi.org/10.1182/blood-2011-02-338665

Published: 2011

Includes: Supplemental data

Journal Articles

Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma

Brian A. Walker, Christopher P. Wardell, Laura Chiecchio, Emma M. Smith, Kevin D. Boyd, Antonino Neri, Faith E. Davies, Fiona M. Ross, Gareth J. Morgan

Blood (2011) 117 (2): 553–562.

https://doi.org/10.1182/blood-2010-04-279539

Published: 2011

Includes: Supplemental data

Journal Articles

Defining High Risk Myeloma Using Co-Segregating FISH Variables; Results of MRC Myeloma IX

Kevin D Boyd, MBBS, Fiona M. Ross, PhD, William J Tapper, PhD, Laura Chiecchio, PhD, GianPaolo Dagrada, Rebecca Protheroe, David Stockley, Zoe Konn, Walter M Gregory, PhD, Brian A Walker, PhD, Christopher P Wardell, PhD, Faith E Davies, MD, Gareth J Morgan, MD, PhD

Blood (2010) 116 (21): 1907.

https://doi.org/10.1182/blood.V116.21.1907.1907

Published: 2010

Journal Articles

Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results

Gareth J Morgan, MD, PhD, Faith E. Davies, MD, Walter M. Gregory, PhD, Sue E. Bell, PhD, Alex J. Szubert, MSc, Nuria Navarro-Coy, MPhil, Mark T. Drayson, MD, PhD, Roger G. Owen, MD, Gordon Cook, MD, Fiona M. Ross, PhD, Graham H. Jackson, MD, J. Anthony Child, MD

Blood (2010) 116 (21): 623.

https://doi.org/10.1182/blood.V116.21.623.623

Published: 2010

Journal Articles

Hypermethylation Is A Key Feature of the Transition of Multiple Myeloma to Plasma Cell Leukemia

Brian A Walker, BSc, PhD, Christopher P Wardell, PhD, Kevin D Boyd, MB.BS, Emma M. Smith, PhD, Mette Nyegaard, Maria Teresa Petrucci, MD, Pellegrino Musto, MD, Hans E Johnsen, MD, DMSc, Antonino Neri, MD, Faith E. Davies, MD, Fiona M. Ross, BSc, DPhil, Gareth J Morgan, MD, PhD

Blood (2010) 116 (21): 535.

https://doi.org/10.1182/blood.V116.21.535.535

Published: 2010

Journal Articles

Deletion 13, Detected by Metaphase Analysis, Is Not a Significant Prognostic Indicator In Myeloma

Fiona M. Ross, DPhil, Laura Chiecchio, PhD, GianPaolo Dagrada, BSc, William J Tapper, PhD, Zoe J Konn, BSc, Kan Luk Cheung, BSc, Rebecca KM Protheroe, BSc, David M Stockley, BSc, Susan E Bell, DPhil, Walter M Gregory, PhD, Alexander J Szubert, MSc, Gordon Cook, MD, Roger G. Owen, MD, Mark T. Drayson, MD, Graham Jackson, DM, Faith Davies, MD, PhD, J. Anthony Child, MD, Gareth J Morgan, MD, PhD

Blood (2010) 116 (21): 2980.

https://doi.org/10.1182/blood.V116.21.2980.2980

Published: 2010

Journal Articles

Optimising Bone Disease In Myeloma; Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX Trial

Gareth J Morgan, MD, PhD, Faith E. Davies, MD, Walter M Gregory, Sue E. Bell, DPhil, Alexander J Szubert, MSc, Mark T. Drayson, MD, John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Roger G. Owen, MD, Gordon Cook, MD, Fiona M. Ross, Dr, Graham H. Jackson, MD, Nigel H. Russell, MD, J. Anthony Child, MD

Blood (2010) 116 (21): 311.

https://doi.org/10.1182/blood.V116.21.311.311

Published: 2010

Journal Articles

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

Brian A. Walker, Paola E. Leone, Laura Chiecchio, Nicholas J. Dickens, Matthew W. Jenner, Kevin D. Boyd, David C. Johnson, David Gonzalez, Gian Paolo Dagrada, Rebecca K. M. Protheroe, Zoe J. Konn, David M. Stockley, Walter M. Gregory, Faith E. Davies, Fiona M. Ross, Gareth J. Morgan

Blood (2010) 116 (15): e56–e65.

https://doi.org/10.1182/blood-2010-04-279596

Published: 2010

Includes: Supplemental data

Journal Articles

Gain of 1q21 Does Not Predict for Immediate Progression in MGUS.

Laura Chiecchio, Gian Paolo Dagrada, Elizabet Dachs Cabanas, Rebecca K.M. Protheroe, David M. Stockley, Zoe J. Konn, Nicholas C.P. Cross, Christine J. Harrison, Fiona M. Ross

Blood (2009) 114 (22): 123.

https://doi.org/10.1182/blood.V114.22.123.123

Published: 2009

Journal Articles

The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS.

Gareth J Morgan, MD, PhD, Faith E Davies, MD, Walter M Gregory, Susan E Bell, Alex J Szubert, Kim Cocks, Nuria Navarro Coy, Mark T Drayson, Roger G Owen, Fiona M Ross, DPhil, Graham H Jackson, J. Anthony Child

Blood (2009) 114 (22): 352.

https://doi.org/10.1182/blood.V114.22.352.352

Published: 2009

NARROW

Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations

Surface IgM Levels Independently Influence Clinical Behavior and Associate with Altered Phenotype and Genetics in Chronic Lymphocytic Leukemia

Expression Quantitative Trait Loci Reveal Regulatory Regions Important In The Pathogenesis of Multiple Myeloma

Co-Existent Hyperdiploidy Does Not Abrogate The Poor Prognosis Associated With Adverse Cytogenetics In Myeloma

Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells

The Impact of Thalidomide Maintenance Therapy Varies Dependent Upon Biological Risk Grouping

Base-Pair Resolution Mapping of IGH Translocations in Multiple Myeloma Using Targeted Capture and Massively Parallel Sequencing

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease

The Interaction of Response and FISH-Based Risk Stratification to Better Define Clinical Outcome in Myeloma

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma

Defining High Risk Myeloma Using Co-Segregating FISH Variables; Results of MRC Myeloma IX

Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results

Hypermethylation Is A Key Feature of the Transition of Multiple Myeloma to Plasma Cell Leukemia

Deletion 13, Detected by Metaphase Analysis, Is Not a Significant Prognostic Indicator In Myeloma

Optimising Bone Disease In Myeloma; Zoledronic Acid Plus Thalidomide Combinations Improves Survival and Bone Endpoints: Results of the MRC Myeloma IX Trial

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

Gain of 1q21 Does Not Predict for Immediate Progression in MGUS.

The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only